New combo vaccine shows promise in halting aggressive lung cancer

NCT ID NCT04487756

Completed Disease control Sponsor: Instituto Oncológico Dr Rosell Source: ClinicalTrials.gov ↗

First seen Jun 03, 2026 · Last updated Jun 09, 2026 · Updated 3 times

Summary

This study tested a maintenance treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer. After standard chemotherapy and an immunotherapy drug, patients received a personalized vaccine made from their own immune cells, plus continued immunotherapy. The goal was to see if this combination could delay cancer progression and improve survival. The trial involved 20 participants across three hospitals in Spain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Hospital Clínic Barcelona

Barcelona, Barcelona, 08036, Spain
ICO Badalona

Badalona, Barcelona, 08916, Spain
Quirón Dexeus

Barcelona, Barcelona, 08028, Spain

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE STAGE SMALL CELL LUNG CANCER